



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12P 21/06, C12N 15/00	A1	(11) International Publication Number: WO 91/10741 (43) International Publication Date: 25 July 1991 (25.07.91)
(21) International Application Number: PCT/US91/00245 (22) International Filing Date: 11 January 1991 (11.01.91) (30) Priority data: 466,008 12 January 1990 (12.01.90) US 610,515 8 November 1990 (08.11.90) US (71) Applicant: CELL GENESYS, INC. [US/US]; 344A Lakeside Drive, Foster City, CA 94404 (US). (72) Inventors: KUCHERLAPATI, Raju ; 8 Gracie Lane, Darien, CT 06820 (US). JAKOBOVITS, Aya ; 2021 Monterey Avenue, Menlo Park, CA 94025 (US).		(74) Agents: ROWLAND, Bertram, I. et al.; Cooley Godward Castro Huddleson & Tatum, Five Palo Alto Square, 4th Floor, Palo Alto, CA 94306 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent). Published <i>With international search report.</i>
(54) Title: GENERATION OF XENOGENEIC ANTIBODIES (57) Abstract <p>The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by repetitive transformations of embryonic stem cells by homologous recombination, preferably in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

5

GENERATION OF XENOGENEIC ANTIBODIES**CROSS-REFERENCE TO RELATED APPLICATIONS**

10

This application is a continuation-in-part of Application Serial No. 07/466,008 filed January 12, 1990.

INTRODUCTION**Technical Field**

15

The field of this invention is the production of xenogeneic specific binding proteins in a viable mammalian host.

Background

20

Monoclonal antibodies find use in both diagnosis and therapy. Because of their ability to bind to a specific epitope, they can be uniquely used to identify molecules carrying that epitope or may be directed, by themselves or in conjunction with another moiety, to a specific site for diagnosis or therapy.

25

30

Monoclonal antibodies comprise heavy and light chains which join together to define a binding region for the epitope. Each of the chains is comprised of a variable region and a constant region. The constant region amino acid sequence is specific for a particular isotype of the antibody, as well as the host which produces the antibody.

35

Because of the relationship between the sequence of the constant region and the species from which the antibody is produced, the introduction of a xenogeneic antibody into the vascular system of the host can produce an immune response. Where the xenogeneic antibody may be introduced repetitively, in the case of chronic diseases, it becomes impractical to administer the antibody, since it will be rapidly

40

destroyed and may have an adverse effect. There have been, therefore, many efforts to provide a source of syngeneic or allogeneic antibodies. One technique has involved the use of recombinant DNA technology where
5 the genes for the heavy and light chains from the host were identified and the regions encoding the constant region isolated. These regions were then joined to the variable region encoding portion of other immunoglobulin genes from another species directed to
10 a specific epitope.

While the resulting chimeric partly xenogeneic antibody is substantially more useful than using a fully xenogeneic antibody, it still has a number of disadvantages. The identification,
15 isolation and joining of the variable and constant regions requires substantial work. In addition, the joining of a constant region from one species to a variable region from another species may change the specificity and affinity of the variable regions, so
20 as to lose the desired properties of the variable region. Also, there are framework and hypervariable sequences specific for a species in the variable region. These framework and hypervariable sequences may result in undesirable antigenic responses.

25 It would therefore be more desirable to produce allogeneic antibodies for administration to a host by immunizing the host with an immunogen of interest. For primates, particularly humans, this approach is not practical. The human antibodies which
30 have been produced have been based on the adventitious presence of an available spleen, from a host which had been previously immunized to the epitope of interest. While human peripheral blood lymphocytes may be employed for the production of monoclonal antibodies,
35 these have not been particularly successful in fusions and have usually led only to IgM. Moreover, it is particularly difficult to generate a human antibody response against a human protein, a desired target in

many therapeutic and diagnostic applications. There is, therefore, substantial interest in finding alternative routes to the production of allogeneic antibodies for humans.

5

Relevant Literature

- Thomas and Capecchi, Cell, 51, 503-512, 1987. Koller and Smithies, Proc. Natl. Acad. Sci. USA, 86, 8932-8935, 1989, describe inactivating the B2microglobulin locus by homologous recombination in embryonic stem cells. Berman et al., EMBO J. 7, 727-738, 1988, describe the human Ig VH locus. Burke, et al., Science, 236, 806-812, 1987, describe yeast artificial chromosome vectors. See also, Garza et al., Science, 246, 641-646, 1989, and Brownstein et al., Science, 244, 1348-1351, 1989. Sakano, et al., describe a diversity segment of the immunoglobulin heavy chain genes. Sakano et al., Nature, 290, 562-565, 1981. Tucker et al., Proc. Natl. Acad. Sci. USA, 78, 7684-7688, 1981, describe the mouse IgA heavy chain gene sequence. Blankenstein and Kruwinkels Eur. J. Immunol., 17, 1351-1357, 1987, describe the mouse variable heavy chain region. See also, Joyner et al., Nature, 338, 153-155, 1989, Traver et al., Proc. Nat. Acad. Sci. USA 86, 5898-5902, 1989, and Panchis et al., Proc. Nat. Acad. Sci. USA, 87, 5109-5113, 1990.

SUMMARY OF THE INVENTION

Xenogeneic specific binding proteins are produced in a non-primate viable mammalian host by immunization of the mammalian host with an appropriate immunogen.

The host is characterized by: (1) being incapable of producing endogenous immunoglobulin; (2) an exogenous immunoglobulin locus comprising at least one immunoglobulin constant region, or protein thereof, immunoglobulin sequences providing for the components of the variable region of at least one of

the light and heavy chains, and at least one intron with appropriate splicing sites for excision and assembly of a functional immunoglobulin subunit. Thus, the mammalian host will comprise at least one
5 xenogeneic constant region or protein thereof capable of being spliced to a functional J region of an endogenous or exogenous immunoglobulin locus, may have an entire immunoglobulin locus of the host substituted by a portion or an entire xenogeneic immunoglobulin
10 locus, or may have a xenogeneic immunoglobulin locus inserted into a chromosome of the host cell and an inactivated endogenous immunoglobulin region. These various alternatives will be achieved, at least in part, by employing homologous recombination at the
15 immunoglobulin loci for the heavy and light chains.

DESCRIPTION OF SPECIFIC EMBODIMENTS

Novel transgenic mammalian hosts, other than primates, particularly other than human, are provided,
20 where the host is capable of mounting an immune response to an immunogen, where the response produces antibodies having primate, particularly human, constant and/or variable regions or such other effector peptide sequences of interest. The hosts are
25 characterized by being capable of producing xenogeneic or modified antibodies as a result of substitution and/or inactivation of the endogenous immunoglobulin subunit encoding loci. The modifications retain at least a portion of the constant regions which provide
30 for assembly of the variable region binding site bonded at the C-terminus to a functional peptide. The functional peptide may take many forms or conformations and may serve as an enzyme, growth factor, binding protein, ligand, cytokine, effector
35 protein, chelating proteins, etc. The antibodies may be any isotype, e.g., IgA, D, E, G or M or subtypes within the isotype.

A number of strategies may be employed to achieve the desired transgenic hosts. Various transgenic hosts may be employed, particularly murine, lagomorpha, ovine, porcine, equine, canine, feline, or the like, normally other than primate. For the most part, mice have been used for the production of B-lymphocytes for immortalization for the production of antibodies. Since mice are easy to handle, can be produced in large quantities, and are known to have an extensive immune repertoire, mice will usually be the animal of choice. Therefore, in the following discussion, the discussion will refer to mice, but it should be understood that other animals, particularly mammals, may be readily substituted for the mice, following the same procedures.

In one strategy, as individual steps, the human heavy and light chain immunoglobulin gene complexes are introduced into the mouse germ line and in a separate step the corresponding mouse genes are rendered non-functional. Human heavy and light chain genes are reconstructed in an appropriate eukaryotic or prokaryotic microorganism and the resulting DNA fragments can be introduced into pronuclei of fertilized mouse oocytes or embryonic stem cells. Inactivation of the endogenous mouse immunoglobulin loci is achieved by targeted disruption of the appropriate loci by homologous recombination in mouse embryonic stem cells. In each case chimeric animals are generated which are derived in part from the modified embryonic stem cells and are capable of transmitting the genetic modifications through the germ line. The mating of mouse strains with human immunoglobulin loci to strains with inactivated mouse loci will yield animals whose antibody production is purely human.

In the next strategy, fragments of the human heavy and light chain immunoglobulin loci are used to directly replace the corresponding mouse loci by

homologous recombination in mouse embryonic stem cells. This is followed by the generation of chimeric transgenic animals in which the embryonic stem cell-derived cells contribute to the germ line.

5 These strategies are based on the known organization of the immunoglobulin chain loci in a number of animals, since the organization, relative location of exons encoding individual domains, and location of splice sites and transcriptional elements, is understood to varying degrees. In the human, the immunoglobulin heavy chain locus is located on chromosome 14. In the 5' - 3' direction of transcription, the locus comprises a large cluster of variable region genes (V_H), the diversity (D) region genes, followed by the joining (J_H) region genes and the constant (C_H) gene cluster. The size of the locus is estimated to be about 2,500 kilobases (kb). During B-cell development, discontinuous gene segments from the germ line IgH locus are juxtaposed by means of a physical rearrangement of the DNA. In order for a functional heavy chain Ig polypeptide to be produced, three discontinuous DNA segments, from the V_H , D, and J_H regions must be joined in a specific sequential fashion; V_H to DJ_H , generating the functional unit V_HDJ_H . Once a V_HDJ_H has been formed, specific heavy chains are produced following transcription of the Ig locus, utilizing as a template the specific $V_HDJ_HC_H$ unit comprising exons and introns. There are two loci for Ig light chains, the κ locus on human chromosome 2 and the λ locus on human chromosome 22. The structure of the IgL loci is similar to that of the IgH locus, except that the D region is not present. Following IgH rearrangement, rearrangement of a light chain locus is similarly accomplished by V_L and J_L joining of the κ or λ chain. The sizes of the λ and κ loci are each approximately 1000 kb. Expression of rearranged IgH and an Ig κ or Ig λ light chain in a

particular B-cell allows for the generation of antibody molecules.

In order to isolate, clone and transfer the IgH_{hu} locus, a yeast artificial chromosome may be employed. The entire IgH_{hu} locus can be contained within one or a few yeast artificial chromosome (YAC) clones. The same is true for the Ig light chain loci. Subsequent introduction of the appropriate heavy chain or light chain YAC clones into recipient yeast allows for the reconstitution of intact germ line Ig loci by homologous recombination between overlapping regions of homology. In this manner, the isolation of DNA fragments encoding the human Ig chain is obtained.

In order to obtain a broad spectrum of high affinity antibodies, it is not necessary that one include the entire V region. Various V region gene families are interspersed within the V region cluster. Thus, by obtaining a subset of the known V region genes of the human heavy and light chain Ig loci (Berman et al., EMBO J. (1988) 7: 727-738) rather than the entire complement of V regions, the transgenic host may be immunized and be capable of mounting a strong immune response and provide high affinity antibodies. In this manner, relatively small DNA fragments of the chromosome may be employed, for example, a reported 670 kb fragment of the Ig_{Hu} locus is shown in Figure 1b. This NotI-NotI restriction fragment would serve to provide a variety of V regions, which will provide increased diversity by recombining with the various D and J regions and undergoing somatic mutation.

In order to provide for the production of human antibodies in a xenogeneic host, it is necessary that the host be competent to provide the necessary enzymes and other factors involved with the production of antibodies, while lacking competent endogenous genes for the expression of heavy and light subunits of immunoglobulins. Thus, those enzymes and other

factors associated with germ line rearrangement, splicing, somatic mutation, and the like, will be functional in the xenogeneic host. What will be lacking is a functional natural region comprising the various exons associated with the production of endogenous immunoglobulin subunits.

The human DNA may be introduced into the pronuclei of fertilized oocytes or embryonic stem cells. The integration may be random or homologous depending on the particular strategy to be employed. Thus, by using transformation, using repetitive steps or in combination with breeding, transgenic animals may be obtained which are able to produce human antibodies in the substantial absence of light or heavy host immunoglobulin subunits.

To inactivate the host immunoglobulin loci, homologous recombination may be employed, where DNA is introduced at the immunoglobulin heavy chain and light chain loci which inhibits the production of endogenous immunoglobulin subunits. Since there are two heavy chain alleles and two light chain loci, each with two alleles, although one may choose to ignore the λ loci, there will have to be multiple transformations which result in inactivation of each of the alleles. (By transformation is intended any technique for introducing DNA into a viable cell, such as conjugation, transformation, transfection, transduction, electroporation, lipofection, biolistics, or the like.) Homologous recombination may be employed to functionally inactivate each of the loci, by introduction of the homologous DNA into embryonic stem cells, followed by introduction of the modified cells into recipient blastocysts. Subsequent breeding allows for germ line transmission of the inactivated locus. One can therefore choose to breed heterozygous offspring and select for homozygous offspring from the heterozygous parents or again one may use the embryonic stem cell for homologous

recombination and inactivation of the comparable locus.

The number of transformation steps may be reduced by providing at least a fragment of the human immunoglobulin subunit locus for homologous recombination with the analogous endogenous immunoglobulin, so that the human locus is substituted for at least a part of the host immunoglobulin locus, with resulting inactivation of the host immunoglobulin subunit locus. Of particular interest is the use of transformation for a single inactivation, followed by breeding of the heterozygous offspring to produce a homozygous offspring. Where the human locus is employed for substitution or insertion into the host locus for inactivation, the number of transformations may be limited to three transformations and as already indicated, one may choose to ignore the less used λ locus and limit the transformations to two transformations. Alternatively, one may choose to provide for inactivation as a separate step for each locus, employing embryonic stem cells from offspring which have previously had one or more loci inactivated. In the event only transformation is used and the human locus is integrated into the host genome in random fashion, a total of eight transformations may be required.

For inactivation, any lesion in the target locus resulting in the prevention of expression of an immunoglobulin subunit of that locus may be employed. Thus, the lesion may be in a region comprising the enhancer, e.g., 5' upstream or intron, in the V, J or C regions, and with the heavy chain, the opportunity exists in the D region, or combinations thereof. Thus, the important factor is that Ig germ line gene rearrangement is inhibited, or a functional message encoding the immunoglobulin subunit cannot be produced, either due to failure of transcription, failure of processing of the message, or the like.

SUBSTITUTE SHEET

Preferably, when one is only interested in inactivating the immunoglobulin subunit locus, the lesion will be introduced into the J region of the immunoglobulin subunit locus. Thus, one produces a construct which lacks a functional J region and may comprise the sequences of the J region adjacent to and upstream and/or downstream from the J region or comprises all or part of the region with an inactivating insertion in the J region. The insertion may be 50 bp or more, where such insertion results in disruption of formation of a functional mRNA. Desirably, the J region in whole or substantial part, usually at least about 75% of the locus, preferably at least about 90% of the locus, is deleted. If desired, the lesion between the two flanking sequences defining the homologous region may extend beyond the J region, into the variable region and/or into the constant region.

Desirably, a marker gene is used to replace the J region. Various markers may be employed, particularly those which allow for positive selection. Of particular interest is the use of G418 resistance, resulting from expression of the gene for neomycin phosphotransferase.

Upstream and/or downstream from the target gene construct may be a gene which provides for identification of whether a double crossover has occurred. For this purpose, the Herpes simplex virus thymidine kinase gene may be employed, since cells expressing the thymidine kinase gene may be killed by the use of nucleoside analogs such as acyclovir or gancyclovir, by their cytotoxic effects on cells that contain a functional HSV-tk gene. The absence of sensitivity to these nucleoside analogs indicates the absence of the HSV-thymidine kinase gene and, therefore, where homologous recombination has occurred, that a double crossover has also occurred.

While the presence of the marker gene in the genome will indicate that integration has occurred, it will still be necessary to determine whether homologous integration has occurred. This can be
5 achieved in a number of ways. For the most part, DNA analysis will be employed to establish the location of the integration. By employing probes for the insert and then sequencing the 5' and 3' regions flanking the insert for the presence of the target locus extending
10 beyond the flanking region of the construct or identifying the presence of a deletion, when such deletion has been introduced, the desired integration may be established.

The polymerase chain reaction (PCR) may be
15 used with advantage in detecting the presence of homologous recombination. Probes may be used which are complementary to a sequence within the construct and complementary to a sequence outside the construct and at the target locus. In this way, one can only
20 obtain DNA chains having both the primers present in the complementary chains if homologous recombination has occurred. By demonstrating the presence of the probes for the expected size sequence, the occurrence of homologous recombination is supported.

25 The construct may further include a replication system which is functional in the mammalian host cell. For the most part, these replication systems will involve viral replication systems, such as Simian virus 40, Epstein-Barr virus, polyoma virus, papilloma virus, and the like. Various
30 transcriptional initiation systems may be employed, either from viruses or from mammalian genes, such as SV40, metallathionein-I and II genes, β -actin gene, adenovirus early and late genes, phosphoglycerate
35 kinase gene, RNA polymerase II gene, or the like. In addition to promoters, wild-type enhancers may be employed to further enhance the expression of the marker gene.

In constructing the subject constructs for homologous recombination, a replication system for procaryotes, particularly E. coli, may be included, for preparing the construct, cloning after each
5 manipulation, analysis, such as restriction mapping or sequencing, expansion and isolation of the desired sequence. Where the construct is large, generally exceeding about 50 kbp, usually exceeding 100 kbp, and usually not more than about 1000kbp, a yeast
10 artificial chromosome (YAC) may be used for cloning of the construct.

Once a construct has been prepared and any undesirable sequences removed, e.g., procaryotic sequences, the construct may now be introduced into
15 the target cell. Any convenient technique for introducing the DNA into the target cells may be employed. Techniques include spheroplast fusion, lipofection, electroporation, calcium phosphate-mediated DNA transfer or direct microinjection. After
20 transformation or transfection of the target cells, target cells may be selected by means of positive and/or negative markers, as previously indicated, neomycin resistance and acyclovir or gancyclovir resistance. Those cells which show the desired
25 phenotype may then be further analyzed by restriction analysis, electrophoresis, Southern analysis, PCR, or the like. By identifying fragments which show the presence of the lesion(s) at the target locus, one can identify cells in which homologous recombination has
30 occurred to inactivate a copy of the target locus.

The above described process may be performed first with a heavy chain locus in an embryonic stem cell and then maturation of the cells to provide a mature fertile host. Then by breeding of the
35 heterozygous hosts, a homozygous host may be obtained or embryonic stem cells may be isolated and transformed to inactivate the second IgH locus, and the process repeated until all the desired loci have

been inactivated. Alternatively, the light chain locus may be the first. At any stage, the human loci may be introduced.

As already indicated, the target locus may
5 be substituted with the analogous human locus. In this way, the human locus will be placed substantially in the same region as the analogous host locus, so that any regulation associated with the position of the locus will be substantially the same for the human
10 immunoglobulin locus. For example, by isolating the entire V_H gene locus (including V, D, and J sequences), or portion thereof, and flanking the human locus with sequences from the mouse locus, preferably sequences separated by at least about 5 kbp, in the
15 host locus, preferably at least about 10 kbp in the host locus, one may insert the human fragment into this region in a recombinational event(s), substituting the human immunoglobulin locus for the variable region of the host immunoglobulin locus. In
20 this manner, one may disrupt the ability of the host to produce an endogenous immunoglobulin subunit, while allowing for the promoter of the human immunoglobulin locus to be activated by the host enhancer and regulated by the regulatory system of the host.

25 Once the human loci have been introduced into the host genome, either by homologous recombination or random integration, and host animals have been produced with the endogenous immunoglobulin loci inactivated by appropriate breeding of the
30 various transgenic or mutated animals, one can produce a host which lacks the native capability to produce endogenous immunoglobulin subunits, but has the capacity to produce human immunoglobulins with at least a significant portion of the human repertoire.

35 The functional inactivation of the two copies of each of the three host Ig loci, where the host contains the human IgH and the human Ig κ and/or λ loci would allow for the production of purely

human antibody molecules without the production of host or host/human chimeric antibodies. Such a host strain, by immunization with specific antigens, would respond by the production of mouse B-cells producing specific human antibodies, which B-cells could be fused with mouse myeloma cells or be immortalized in any other manner for the continuous stable production of human monoclonal antibodies.

The subject methodology and strategies need not be limited to producing complete immunoglobulins, but provides the opportunity to provide for regions joined to a portion of the constant region, e.g., C_{H1} , C_{H2} , C_{H3} , or C_{H4} , or combination thereof. Alternatively, one or more of the exons of the C_H and C_K or C_λ regions may be replaced or joined to a sequence encoding a different protein, such as an enzyme, e.g., plasminogen activator, superoxide dismutase, etc.; toxin A chain, e.g., ricin, abrin, diphtheria toxin, etc.; growth factors; cytotoxic agent, e.g., TNF, or the like. See, for example, WO 89/07142; WO 89/09344; and WO 88/03559. By inserting the protein of interest into a constant region exon and providing for splicing of the variable region to the modified constant region exon, the resulting binding protein may have a different C-terminal region from the immunoglobulin. By providing for a stop sequence with the inserted gene, the protein product will have the inserted protein as the C-terminal region. If desired, the constant region may be entirely substituted by the other protein, by providing for a construct with the appropriate splice sites for joining the variable region to the other protein.

The antibodies or antibody analog producing B-cells from the transgenic host may be used for fusion to a mouse myeloid cell to produce hybridomas or immortalized by other conventional process, e.g., transfection with oncogenes. These immortalized cells

may then be grown in continuous culture or introduced into the peritoneum of a compatible host for production of ascites.

5 The subject invention provides for the production of polyclonal human anti-serum or human monoclonal antibodies or antibody analogs. Where the mammalian host has been immunized with an immunogen, the resulting human antibodies may be isolated from other proteins by using an affinity column, having an
10 Fc binding moiety, such as protein A, or the like.

For producing animals from embryonic stem cells, after transformation, the cells may be plated onto a feeder layer in an appropriate medium, e.g. fetal bovine serum enhanced DMEM. Cells containing the
15 construct may be detected by employing a selective medium and after sufficient time for colonies to grow, colonies may be picked and analyzed for the occurrence of integration or homologous recombination. As described previously, the PCR may be used, with
20 primers within or without the construct sequence, but at the target locus.

Those colonies which show homologous recombination may then be used for embryo manipulation and blastocyst injection. Blastocysts may be obtained
25 from females by flushing the uterus 3-5 days after ovulation. The embryonic stem cells may then be trypsinized and the modified cells added to a droplet containing the blastocyst. At least one and up to thirty modified embryonic stem cells may be injected
30 into the blastocoel of the blastocyst. After injection, at least one and no more than about fifteen of the blastocysts are returned to each uterine horn of pseudo-pregnant females. Females are then allowed to go to term and the resulting litter screened for
35 mutant cells having the construct.

The mammals may be any non-human, particularly non-primate mammal, such as laboratory animals, particularly small laboratory animals, such

as mice, rats, guinea pigs, etc., domestic animals, pets, etc.

The following examples are offered by way of illustration and not by way of limitation.



5

EXPERIMENTAL

Inactivation of the mouse heavy chain J genes

Construction of the inactivation vector

10 A 6.4 Kb EcoRI fragment, containing the mouse heavy chain J genes and flanking sequences, is cloned from a Balb/c mouse embryo genomic library using the probes described in Sakano *et al.*, *Nature* 290:562-565, 1981. This fragment (mDJ) is inserted
15 into EcoRI-digested pUC19 plasmid (pmDJ). A 2.9 Kb fragment, containing the 4 J genes, is deleted by XhoI-ScaI digestion (pmD δ JNeo, see Chart 1). An 1150 bp XhoI-BamHI fragment, containing a neomycin-resistance gene driven by the Herpes simplex virus
20 thymidine kinase gene (HSV-tk) promoter and a polyoma enhancer is isolated from pMC1Neo (Thomas and Capecchi, *Cell*, 51, 503-512, 1987). A synthetic adaptor is added onto this fragment to convert the BamHI end into a ScaI end and the resulting fragment
25 is joined to the XhoI-ScaI pmD δ J to form the inactivation vector (pmD δ J.Neo) in which the 5' to 3' orientation of the neomycin and the heavy chain promoters is identical. This plasmid is linearized by NdeI digestion before transfection to ES
30 cells. The sequences driving the homologous recombination event are 3 kb and 0.5 kb fragments, located 5' and 3' to the neomycin gene, respectively.

Chart 1**Mouse Heavy Chain J Genes Inactivation Vector****(A) Targeted mouse heavy chain J genes****(B) Inactivation vector mDAJ.Neo**



The ES cell line E14TG2a (Hooper et al., Nature, 326:292-295, 1987) is cultured on mitomycin-treated primary embryonic fibroblast-feeder layers essentially as described (Doetschman et al., J. Embryol. Exp. Morphol. 87:27-45, 1985). The embryonic fibroblasts are prepared from embryos from C57BL/6 females that are mated 14 to 17 days earlier with a male homozygous for a neomycin transgene (Gossler et al., PNAS 83:9065-9069, 1986). These cells are capable of growth in media containing G418. Electroporation conditions are described by (Boggs et al., Ex. Hematol. (NY) 149:988-994, 1986). ES cells are trypsinized, resuspended in culture media at a concentration of 4×10^7 /ml and electroporated in the presence of the targeting DNA at a concentration of 12nM in the first experiment and 5nM DNA in the second. A voltage of 300 V with a capacitance of 150-250 μ F is found optimal with an electroporation cell of 5 mm length and 100 mm² cross-section. 5×10^6 electroporated cells are plated onto mitomycin-treated fibroblasts in 100 mm dishes in the presence of Dulbecco's modified Eagle's media (DMEM) supplemented with 15% fetal bovine serum (FBS) and 0.1 mM 2-mercaptoethanol. The media is replaced 24 hr after electroporation with media containing 200 μ g/ml G418.

ES colonies resulting 10-14 days after electroporation are picked with drawn out capillary pipettes for analysis using PCR. Half of each picked colony is saved in 24-well plates already seeded with mitomycin-treated feeder cells. The other halves, combined in pools of 3-4, are transferred to Eppendorf tubes containing approximately 0.5 ml of PBS and analyzed for homologous recombination by PCR. Conditions for PCR reactions are essentially as described (Kim and Smithies, Nucleic Acids Res. 16:8887-8893, 1988). After pelleting, the ES cells are resuspended in 5 μ l of PBS and are lysed by the


addition of 55 μ l of H₂O to each tube. DNases are inactivated by heating each tube at 95°C for 10 min. After treatment with proteinase K at 55°C for 30 min, 30 μ l of each lysate is transferred to a tube
5 containing 20 μ l of a reaction mixture including PCR buffer: 1.5 μ g of each primer, 3U of Taq polymerase, 10% DMSO, and dNTPs, each at 0.2 mM. The PCR expansion employs 55 cycles using a thermocycler with 65 seconds melt at 92°C and a 10 min annealing and
10 extension time at 65°C. The two priming oligonucleotides are TGGCGGACCGCTATCCCCCAGGAC and TAGCCTGGGTCCCTCCTTAC, which correspond respectively to a region 650 bases 3' of the start codon of the neomycin gene and sequences located in the mouse heavy
15 chain gene, 1100 bases 3' of the insertion site. 20 μ l of the reaction mix is electrophoresed on agarose gels and transferred to nylon membranes (Zeta Bind). Filters are probed with a ³²P-labelled fragment of the 991 bp XbaI fragment of the J-C region.

Chart 2


(A) Targeted mouse heavy chain J genes

(B) Inactivation vector pmH δ J(C) Southern analysis of pmH δ J-targeted ES colonies

Wild type ES cell genome



Targeted ES cell genome



Inactivation of the mouse Ig heavy chain J genes in ES cells.

Construction of the inactivation vector

A 6.1-Kb EcoRI fragment, containing the mouse immunoglobulin heavy chain J region genes and flanking sequences, cloned from a Balb/c mouse embryo genomic library and inserted into pUC18 (pJH), was digested with XhoI and NaeI to delete an about 2.3 kbp fragment containing the four J genes (see Chart 2A). An about 1.1 kbp XhoI-BamHI fragment, blunted at the BamHI site, containing a neomycin resistance gene driven by the Herpes simplex virus thymidine kinase gene (HSV-tk) promoter and polyoma enhancer was isolated from pMC1Neo (Thomas and Capecchi, Cell, 51, 503-512, 1987). This fragment was inserted into the XhoI-NaeI deleted pJH to form the inactivation vector (pmH δ J, see Chart 2B), in which the transcriptional orientation of the neomycin and the heavy chain genes is the same. This plasmid was linearized by NdeI digestion before transfection to ES cells. The sequences driving the homologous recombination event are about 2.8 kbp and about 1.1 kbp fragments, located 5' and 3' to the neomycin gene, respectively.

Culturing, Electroporation, and Selection of ES cells

The ES cell line E14TG2a (Koller and Smithies, 1989, PNAS, USA, 86, 8932-8935) was cultured on mitomycin C-treated embryonic fibroblast feeder layers as described (Koller and Smithies, 1989, PNAS USA, 86, 8932-8935). ES cells were trypsinized, resuspended in HBS buffer (pH 7.05; 137mM NaCl, 5mM KCl, 2mM CaCl₂, 0.7mM Na₂HPO₄, 21mM HEPES pH7.1) at a concentration of 2x10⁷/ml and electroporated in the presence of 50 μ g/ml of the linearized inactivation vector. Electroporation was carried out with a BioRad Gene Pulser using 240 volts and 500 μ F capacitance. 5x10⁶ electroporated cells were plated onto mitomycin C-treated fibroblasts in 100mm dishes in the presence

of Dulbecco's modified Eagle's media (DMEM) supplemented with 15% fetal bovine serum and 0.1 mM 2-mercaptoethanol. The media was replaced 24 hr after electroporation with media containing 200 μ g/ml G418.

5 G418-resistant ES colonies resulting 12-14 days after electroporation were picked with drawn out capillary pipettes for analysis using the polymerase chain reaction (PCR). Half of each picked colony was transferred to an individual well of a 24-well plate,

10 already seeded with mitomycin C-treated feeder cells. The other halves, combined in pools of four, were transferred to Eppendorf tubes containing 0.3 ml of PBS and cell lysates were prepared for PCR analysis as described by Joyner *et al* (*Nature*, 338:153-155, 1989).

15 The PCR reaction included 5-20 μ l of the cell lyste, 1 μ M of each primer, 1.5u of Taq polymerase and 200 μ M of dNTPs. The PCR amplification employed 45 cycles using a thermal cycler (Perkin-Elmer Cetus), with 1 min. melt at 94°C, 2 min. annealing at 55°C, and 3

20 min. extension at 72°C. The two priming oligonucleotides are ACGGTATCGCCGCTCCCGAT and AGTCACTGTAAAGACTTCGGGTA, which correspond respectively to about 120 bases 5' of the BamHI site of the neomycin gene, and to the sequences located in the

25 mouse heavy chain gene, about 160 bases 3' of the insertion site. Successful homologous recombination gives rise to an about 1.4 kbp fragment. 20 μ l of the reaction mixture is electrophoresed on 1% agarose gels, stained with ethidium bromide and transferred to

30 nylon membranes (Gene Screen). Filters were probed with a ³²P-labelled EcoRI-PstI about 1.4 kbp fragment located in the mouse heavy chain, 3' of the insertion site (see Chart 2). For further analysis, genomic DNA was prepared from ES cells, digested with restriction

35 enzymes as recommended by the manufacturers, and fragments were separated on 1% agarose gels. DNA was transferred to nylon membranes (Gene Screen) and

probed with the ^{32}P -labelled fragment as described above.

Analysis of G418-resistant ES colonies

5 In the first experiment, PCR analysis of the pooled colonies detected one positive PCR signal of the expected size (about 1.4kbp) out of 34 pools representing 136 G418-resistant colonies. The four individual colonies that had contributed to this
10 positive pool were analyzed individually by PCR, and a positive clone, ES33D5, was identified. Similar analysis of 540 G418-resistant colonies obtained in the second experiment yielded 4 additional positive clones (ES41-1, ES61-1, ES65-1, ES110-1).

15 In order to verify the targeting disruption of one copy of the J genes, (the gene is autosomal and thus present in two copies), the PCR positive clones were expanded and genomic DNA was prepared, digested with HindIII or with SacI and analyzed by Southern
20 analysis as described using the EcoRI-PstI probe.

 The replacement of the J genes by insertion of the neomycin gene by an homologous recombination event results in an HindIII fragment, detectable with the EcoRI-PstI probe, which is about 1.9 kbp longer
25 than the equivalent fragment in the native locus, due to the loss of two HindIII sites located in the deleted J gene region (see Chart 2C). Southern analysis of each of the 5 positive clones by HindIII digestion gave a pattern which indicated that one of
30 the two copies of the heavy chain J genes had been disrupted. Three labelled fragments were detected: one fragment (about 760 bp), identical in size to that present in untreated cells at the same intensity, one fragment (about 2.3kbp) identical in size to that
35 present in untreated cells, but of decreased intensity in the PCR positive clone, and an additional fragment about 4.2 kbp, the size predicted for an homologous

recombination event, present only in the PCR-positive clones. Similarly, the replacement of the J genes by the neomycin gene by an homologous recombination event results in a loss of one SacI site and the appearance of a fragment, detectable with the EcoRI-PstI probe, which is about 570 bp smaller than the equivalent fragment in the native locus (see Chart 2C). Southern analysis of the clones by SacI digestion gave the expected pattern of one native and one targeted allele: about 4.0 kbp fragment, identical in size to that detected in untreated cells, but of decreased intensity in the 5 positive clones, and an additional fragment of about 3.4 kbp, the size predicted for a targeted homologous recombination event, present only in the identified clones. Rehybridization of the Southern blots with a probe for the neomycin gene shows that only the 4.2 kbp and 3.4 kbp fragments, resulting from the HindIII and the SacI digestion, respectively, hybridized to the probe as predicted by the targeting event.

Inactivation of mouse immunoglobulin heavy chain J
genes in mice


Injection of targeted ES cells into mouse blastocysts
and generation of chimeric offsprings

Mice were purchased from Jackson Laboratories (Bar Harbor, ME). Three and a half day old C57BL/6 blastocysts were obtained from 4-5 week old superovulated females as described by Koller et al. 1989 (supra). ES cells were trypsinized, washed once with fresh DMEM media and diluted to about 1×10^6 /ml in M2 media. About 5μ l of cells were added to a 150μ l droplet of M2 media, under paraffin oil, containing the blastocysts. Ten to fifteen cells were injected into the blastocoel of each blastocyst. Six to nine ES cell-containing blastocysts were returned to each uterine horn of C57BL/6 x DBA F1

pseudopregnant females mated 2.5 days previously with vasectomized males. Pups derived from the injected blastocysts were generally born 16-18 days later. The contribution of the ES cells to the offspring was judged visually by examination of the coat color of the pups. The blastocysts were obtained from C57BL/6 mice, which are solid black in color. The ES cell line E14TG2a, the parental line from which the targeted cell lines were derived, was isolated from 129/Ola mice. This mouse strain is cream in color, the combined effect of three color genes, the dominant AW allele at the agouti locus, the recessive pink-eyed-dilute allele at the p locus and the recessive C^{ch} allele at the C locus. Offspring in which the ES cells participated in the formation of the animal had coats containing brown and cream hair. The ES cell line ES41-1 carrying inactivated mouse immunoglobulin heavy chain, was injected into C57BL/6 mouse blastocysts as described above. Six out of the 18 surviving pups had a high degree of coat color chimerism (70-90%). PCR analysis of DNA isolated from chimeric newborn pups from a female implanted with blastocysts injected with the inactivated ES cells, indicated that the mutated immunoglobulin heavy chain locus is present in a variety of organs such as spleen, thymus, kidney, liver, brain and skin.

Inactivation of the mouse Ig kappa chain J
genes in ES cells

A 5.6 Kb HindIII-BamHI fragment, containing the mouse immunoglobulin kappa chain J region genes and 3' flanking sequences, cloned from a Balb/c mouse embryo genomic library and inserted into pBluescriptSK vector to yield the plasmid (pKJ). pKJ was digested with HindIII and PstI to delete an about 1.7 Kb fragment containing the 5 J genes (see Chart 3). A 570 bp blunt HindIII fragment, spanning the

Chart 3Kappa chain inactivation vector

region 5' to the HindIII site adjacent to the kappa J region, was cloned from mouse genomic DNA by polymerase chain reaction (PCR). This fragment was
5 inserted into HindIII-SmaI digested pIC cloning vector (Marsh et al., 1984, Gene, 32:481-485) and was excised by digestion with KpnI-XhoI. An about 1.1 Kb XhoI-BamHI fragment, blunted at the BamHI site, containing the neomycin resistance gene driven by the
10 Herpes simplex virus thymidine kinase gene (HSV-tk) promoter and polyoma enhancer was isolated from pMC1Neo (Thomas and Capecchi, 1987, supra). The neomycin fragment was inserted into the HindIII-PstI deleted pKJ, which was blunted at the PstI site, 5' to
15 the kappa sequences. The resulting plasmid was digested with KpnI and XhoI and the 570 bp KpnI-XhoI kappa fragment was inserted into the KpnI-XhoI cleaved vector, 5' to the neomycin gene, to generate the
20 inactivation vector (pmK δ J, see chart 3). The transcriptional orientation of the neomycin and the kappa chain genes is the same in pmK δ J. The plasmid was linearized by ApaLI before transfection into ES cells. The linearized sequence has about 3.8 Kb and
25 570 bp of homology to the cellular sequences, located 3' and 5' to the neomycin gene, respectively.

Analysis of G418-resistant ES colonies

Electroporation of the kappa inactivation vector into ES cells and screening for homologous
30 recombination events was carried out as described for the inactivation of the immunoglobulin heavy chain. G418-resistant ES colonies were analysed for homologous recombination targeting by PCR using two
35 priming oligonucleotides CGGTTGCTGTTGTATCCATAACTC and CATCAGAGCAGCCGATTGTCTG, which correspond respectively to the sequences located in the mouse kappa chain gene, about 67 bp 5' of the insertion site, and about 370 bp 3' of the XhoI site of the neomycin gene. A

³²P-labelled 80 base oligonucleotide, which starts about 10 bp 5' of the insertion site, was used as a probe to detect the targeted PCR product. Successful homologous recombination gives rise to an about 1030 bp fragment. PCR analysis of 650 G418-resistant colonies detected 3 positive colonies (ES56-1, ES69-4, ES147-1). Southern analysis of these colonies confirmed the integration of the inactivation vector into one allele of the kappa immunoglobulin loci leading to a deletion of the J region.

Production of human Ig in transgenic mice

Example: production of human heavy chain in transgenic mice DNA vector

An SpeI fragment, spanning the human heavy chain VH6-D-J-C μ -C δ region (Berman *et al.*, *EMBO J.* (1988) 7: 727-738; see Chart 4) is isolated from a human library cloned into a yeast artificial chromosome (YAC) vector (Burke, *et al.*, *Science*, 236: 806-812) using DNA probes described by Berman *et al.* (*EMBO J.* (1988) 7:727-738). One clone is obtained which is estimated to be about 100 Kb. The isolated YAC clone is characterized by pulsed-field gel electrophoresis (Burke *et al.*, *supra*; Brownstein *et al.*, *Science*, 244: 1348-1351), using radiolabelled probes for the human heavy chain (Berman *et al.*, *supra*).

Introduction of YAC clones into embryos

High molecular weight DNA is prepared in agarose plugs from yeast cells containing the YAC of interest (i.e., a YAC containing the aforementioned SpeI fragment from the IgH locus). The DNA is size-fractionated on a CHEF gel apparatus and the YAC band is cut out of the low melting point agarose gel. The gel fragment is equilibrated with polyamines and then melted and treated with agarase to digest the agarose.

The polyamine-coated DNA is then injected into the male pronucleus of fertilized mouse embryos which are surgically introduced into the uterus of a pseudopregnant female as described above. The transgenic nature of the newborns is analyzed by a slot-blot of DNA isolated from tails and the production of human heavy chain is analyzed by obtaining a small amount of serum and testing it for the presence of Ig chains with rabbit anti-human antibodies.

As an alternative to microinjection, YAC DNA is transferred into murine ES cells by ES cell: yeast protoplast fusion (Traver *et al.*, 1989 *Proc. Natl. Acad. Sci., USA*, 86:5898-5902; Pachnis *et al.*, 1990, *ibid* 87: 5109-5113). First, the neomycin-resistance gene from pMC1Neo and a yeast selectable marker are inserted into nonessential YAC vector sequences in a plasmid. This construct is used to transform a yeast strain containing the IgH YAC, and pMC1Neo is integrated into vector sequences of the IgH YAC by homologous recombination. The modified YAC is then transferred into an ES cell by protoplast fusion (Traver *et al.*, 1989; Pachnis *et al.*, 1990), and resulting G418-resistant ES cells which contain the intact human IgH sequences are used to generate chimeric mice.

Production of human Ig by chimeric mice
Construction of human heavy chain replacement vector.

The replacing human sequences include the SpeI 100 kbp fragment of genomic DNA which encompasses the human VH6-D-J-C μ -C δ heavy chain region isolated from a human-YAC library as described before. The flanking mouse heavy chain sequences, which drive the homologous recombination replacement event, contain a 10 kbp BamHI fragment of the mouse C ϵ -C α heavy chain and a 5' J558 fragment comprising the 5' half of the J558 fragment of the mouse heavy chain variable


region, at the 3' and 5' ends of the human sequences, respectively (Chart 4). These mouse sequences are isolated from a mouse embryo genomic library using the probes described in Tucker *et al.*, PNAS USA, 78:

5 7684-7688, 1981, and Blankenstein and Krawinkel (1987, *supra*), respectively. The 1150 bp XhoI to BamHI fragment, containing a neomycin-resistance gene driven by the Herpes simplex virus thymidine kinase gene (HSV-tk) promoter and a polyoma enhancer is
10 isolated from pMC1Neo (Koller and Smithies, 1989, *supra*). A synthetic adaptor is added onto this fragment to convert the XhoI end into a BamHI end and the resulting fragment is joined to the BamHI mouse C ϵ -C α in a plasmid.


15 From the YAC clone containing the human heavy chain locus, DNA sequences from each end of the insert are recovered either by inverse PCR (Silverman *et al.*, PNAS, 86:7485-7489, 1989), or by plasmid rescue in *E. coli*, (Burke *et al.*, 1987; Garza *et al.*
20 Science, 246:641-646, 1989; Traver *et al.*, 1989) (see Chart 4). The isolated human sequence from the 5'V6 end of the YAC is ligated to the mouse J558 sequence in a plasmid and likewise, the human sequence derived from the 3'C δ end of the YAC is ligated to the Neo
25 gene in the plasmid containing Neo and mouse C ϵ -C α described above. The human V6-mouse J558 segment is now subcloned into a half-YAC cloning vector that includes a yeast selectable marker (HIS3) not present in the original IgH YAC, a centromere (CEN) and a single telomere (TEL). The human C δ - Neo - mouse C ϵ
5 - C α is likewise subcloned into a separate half-YAC vector with a different yeast selectable marker (LEU2) and a single TEL. The half-YAC vector containing the human V6 DNA is linearized and used to transform a yeast strain that is deleted for the chromosomal HIS3
10 and LEU2 loci and which carries the IgH YAC. Selection for histidine-prototrophy gives rise to

Chart 4


(A) Human heavy chain locus



(B) Mouse heavy chain locus



(C) Human heavy chain replacement YAC vector



SUBSTITUTE SHEET

yeast colonies that have undergone homologous recombination between the human V6 DNA sequences and contain a recombinant YAC. The half-YAC vector containing the human C δ DNA is then linearized and used to transform the yeast strain generated in the previous step. Selection for leucine-prototrophy results in a yeast strain containing the complete IgH replacement YAC (see Chart 4). This YAC is isolated and introduced into ES cells by microinjection as described previously for embryos.

In accordance with the above procedures, an antigenic or chimeric non-primate host, particularly a mouse host, may be produced which can be immunized to produce human antibodies or analogs specific for an immunogen. In this manner, the problems associated with obtaining human monoclonal antibodies are avoided, since mice can be immunized with immunogens which could not be used with a human host. Furthermore, one can provide for booster injections and adjuvants which would not be permitted with a human host. The resulting B-cells may then be used for immortalization for the continuous production of the desired antibody. The immortalized cells may be used for isolation of the genes encoding the immunoglobulin or analog and be subjected to mutation by in-vitro mutagenesis or other mutagenizing technique to modify the properties of the antibodies. These mutagenized genes may then be returned to the immortalized cells for homologous recombination to provide for a continuous mammalian cellular source of the desired antibodies. The subject invention provides for a convenient source of human antibodies, where the human antibodies are produced in analogous manner to the production of antibodies in a human host. The mouse cells conveniently provide for the activation and rearrangement of human DNA in mouse cells for production of human antibodies.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

WHAT IS CLAIMED IS:

1. A method for producing xenogeneic primate antisera or antibody analog in a mammalian non-primate host, said method comprising:
 - immunizing said host with an immunogen under conditions to stimulate an immune response to said immunogen, whereby said host mounts an immune response to said immunogen and produces plasma cells, B-cells having surface immunoglobulin specific for said immunogen and antibodies specific for said immunogen, wherein said non-primate host is characterized by being substantially incapable of expressing, (1) an endogenous immunoglobulin heavy chain; and, (2) at least one endogenous light chain; and capable of expressing an exogenous primate heavy chain and light chain or analog.
2. A method according to Claim 1, wherein said host is a mouse.
3. A method according to Claim 1, wherein said analog comprises a variable region joined by a peptide bond to a peptide other than solely the immunoglobulin constant region.
4. A method according to Claim 1, wherein said antisera is human antisera.
5. A method according to Claim 1, including the additional step of immortalizing said B-cells for production of monoclonal antibodies.
6. A method according to Claim 1, wherein said host comprises B-cells comprising a functional immunoglobulin locus comprising an exogenous variable region and at least one human constant region.

7. A method according to Claim 1, wherein said host comprises at least a functional portion of human immunoglobulin loci for a heavy chain and a light chain and inactivated endogenous loci for the two copies of the heavy chain and the two copies of at least one light chain type, so as to be substantially incapable of expressing an endogenous antibody subunit.

8. A transgenic non-primate mammal comprising a genome comprising:
at least a functional portion of human immunoglobulin loci for at least a portion of the heavy chain domain and a light chain domain and inactivated endogenous loci for the two copies of the heavy chain and the two copies of at least one light chain type, so as to be substantially incapable of expressing an endogenous antibody subunit.

9. A transgenic non-primate mammal according to Claim 8, wherein said human immunoglobulin loci are at the analogous endogenous loci.

10. A transgenic non-primate mammal according to Claim 8, wherein said human immunoglobulin loci are at other than the analogous endogenous loci.

11. A transgenic non-primate mammal according to Claim 8, wherein said mammal is murine.

12. A transgenic non-primate mammal according to Claim 8, wherein said at least a portion of the heavy chain domain comprises at least one constant type region.

13. A transgenic non-primate mammal according to Claim 8, wherein said at least a portion of the heavy chain domain comprises a peptide sequence other than a constant region.

5

14. A transgenic mouse comprising a genome comprising:

10 inactivated loci of both copies of the immunoglobulin heavy chain and both copies of at least one type of light chain as a result of at least one of a deletion or insertion at the loci; and

at least a functional portion of human immunoglobulin loci for a heavy chain and a light chain.

15

15. A transgenic mouse according to Claim 14, wherein said at least a functional portion comprises only a portion of the variable region.

20

16. A transgenic mouse comprising a genome comprising:

25 inactivated loci of both copies of the immunoglobulin heavy chain and both copies of at least one type of light chain as a result of at least one of a deletion or insertion at the loci; and

at least a functional portion of human immunoglobulin loci for a heavy chain and a light chain, wherein the constant region of at least one of said heavy chain and said light chain comprises a sequence other than said constant region sequence.

30

17. A transgenic non-primate mammal comprising a genome comprising:

35 at least a functional portion of human immunoglobulin loci for at least a portion of the heavy chain and a light chain and inactivated endogenous loci as a result of homologous recombination at said loci for the two copies of the

heavy chain and the two copies of at least one light chain type, so as to be substantially incapable of expressing an endogenous antibody subunit.

5 18. A transgenic non-primate mammal according to Claim 17, wherein said mammal is a mouse and said human immunoglobulin heavy and light chain loci are at mouse immunoglobulin heavy and light chain loci, respectively.

10 19. A non-primate embryonic stem cell comprising a lesion in the J region of one immunoglobulin locus resulting in the incapacity to rearrange to a functional subunit of an
15 immunoglobulin.

 20. A stem cell according to Claim 19, wherein said subunit is the heavy chain.

20 21. A stem cell according to Claim 20, wherein said non-primate is a mouse.

 22. A stem cell according to Claim 19, wherein said lesion is an insertion.
25

 23. A stem cell according to Claim 22, wherein said insertion is a marker capable of selection.

30 24. A stem cell according to Claim 19 wherein said lesion is a deletion.

 25. A stem cell according to Claim 19, wherein said non-primate is a mouse.
35

INTERNATIONAL SEARCH REPORT

International Application

PCT/US 91/00245

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)

According to International Patent Classification (IPC) or to both National Classification and IPC

see attached sheet

II. FIELDS SEARCHED

Minimum Documentation Searched *

Classification System

Classification Symbols

see attached sheet

Documentation Searched other than Minimum Documentation
to the extent that such Documents are included in the Fields Searched *

see attached sheet

III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹

Category *	Citation of Document, ^{1a} with indication, where appropriate, of the relevant passages ^{1b}	Relevant to Claim No. ^{1c}
------------	--	-------------------------------------

see attached sheet

* Special categories of cited documents: ^{1d}

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search ²

Date of Mailing of this International Search Report ²

14 MARCH 1991

26 APR 1991

International Searching Authority ¹

Signature of Authorized Officer ^{2b}

ISA/US

Gabrielle E. Bugatsky
GABRIELLE E. BUGATSKY

PCT/US/ 91/00245

Attachment to Form PCT/ISA/210

I. Classification of subject matter

IPC(5): C12P 21/06; C12N 15/00

U.S. Cl.: 435/69.1, 172.3; 800/2

II. Fields searched

U.S. Cl. 435/69.1, 69.6, 70.1, 172.3; 436/547; 530/387; 800/2;
935/22, 65, 106

Databases: Dialog Information Services Online (File sets Medline
and World Patent Index)

Automated Patent System (File USPAT)

gene transfer or gene replacement or gene inactivation,
homologous recombination; embryonic stem cell, animal stem cell,
embryonal carcinoma, transgenic animal or mammal, xenogeneic
antibody or antiserum or immune response, immunoglobulin;
immunoglobulin gene.

III. Documents considered relevant

Category	Citation	Claims
Y,P	US, A. 4,959,313 (TAKETO) 25 September, 1990 see entire document.	19-25
Y,P	US, A. 4,950,599 (BERTLING) 21 August, 1990 see entire document.	8-25
Y	Proc. Natl. Acad. Sci., USA. Vol. 83, issued April 1986, K.-I. Yamamura, et al., "Cell-type-specific and regulated expression of a human γ 1 heavy-chain immunoglobulin gene in transgenic mice", pages 2152-2156, see entire document.	1-25
Y	Proc. Natl. Acad. Sci., USA. Vol. 86, issued November 1989, B. Koller, et al., "Inactivating the δ 2-microglobulin gene in mouse embryonic stem cells by homologous recombination", pages 8932-8935, see entire document.	1-25
A	Proc. Natl. Acad. Sci., USA. Vol. 83, issued July 1986, D. Ayares, et al., "Sequence homology requirements for intermolecular recombination in mammalian cells", pages 5199-5203, see entire document.	8-25
A	Proc. Natl. Acad. Sci., USA. Vol. 85, issued February 1988, R. Brinster, et al., "Introns increase transcriptional efficiency in transgenic mice", pages 836-840, see entire document.	1-25
Y	Prog. Nucleic Acid Res. Mol. Biol., Vol 36, issued 1989, R. Kucherlapati, "Homologous recombination in mammalian somatic cells", pages 301-310, see entire document.	1-25
Y	Proc. Natl. Acad. Sci., USA. Vol. 86, issued October 1989, A. Shimizu, et al., "Immunoglobulin double-isotype expression by trans-mRNA in a human immunoglobulin transgenic mouse", pages 8020-8023, see entire document.	1-25

Attachment to Telephone Memorandum
PCT/US91/00245

Observations where unity of invention is lacking

Detailed reasons for holding lack of Unity of Invention.

There are three groups of claims: Group I is a method for producing antisera; transgenic animals; Group II is for embryonic stem cells. Group I is related as first mentioned product and process of use. Group II consists of a second mentioned product, which can exist independently of the first mentioned product. PCT Rules 13.1 and 13.2 do not provide for multiple products.

Itemized summary of claims groupings

I. Claims 1-7, drawn to a method for producing xenogeneic antisera, classified in Class 435, subclass 69.1.

Claims 8-18, drawn to transgenic animals with lesions in endogenous immunoglobulin genes, so that they can only express human immunoglobulin genes, classified in Class 800, subclass 2.

II. Claims 19-25, drawn to embryonic stem cells with lesions in endogenous immunoglobulin genes, classified in Class 435, subclass 230.1.